Premarin WHI Results May Mean Additional Labeling Changes, FDA Says
Executive Summary
FDA may request additional changes to the labeling of hormone replacement therapies based on the findings from the terminated Premarin arm of the Women's Health Initiative
You may also be interested in...
Premarin Memory Data Mixed On Dementia Risk; 91% Of Rxs For Menopause
Prescriptions for Wyeth's Prempro and Premarin have almost completely shifted to the relief of vasomotor symptoms in the two years since the first publication of negative findings from the Women's Health Initiative
Premarin Memory Data Mixed On Dementia Risk; 91% Of Rxs For Menopause
Prescriptions for Wyeth's Prempro and Premarin have almost completely shifted to the relief of vasomotor symptoms in the two years since the first publication of negative findings from the Women's Health Initiative
Effexor Follow-On Will Launch One Year Before XR Patent Expires, Wyeth Says
Wyeth expects to have about one year to switch Effexor XR patients to its follow-on serotonin and norepinephrine reuptake inhibitor DVS-233 before venlafaxine XR loses market exclusivity in 2008